Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of September 2026. The report documents the results of the Company's Annual General Meeting of Shareholders held on September 4, 2026, at its principal executive offices in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes
Shareholders approved Proposals Nos. 1(a) and 2-4 as detailed in the proxy statement filed on July 31, 2026. Consequently, the composition of the Board of Directors was confirmed effective as of the end of the meeting.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future operations. It notes that the report is incorporated by reference into the Company's registration statements on Forms F-3 and S-8.
Current Board of Directors
- Mr. Nir Nimrodi
- Dr. Adrian Percy
- Mr. Leon Y. Recanati
- Mr. Dan Falk
- Dr. Yael Margolin
- Mr. Yoshinori Oikawa
- Mr. Ofer Haviv (CEO and President)
Investor Verification Checklist
- Verify the specific details of Proposals Nos. 1(a) and 2-4 in the proxy statement filed on July 31, 2026 (Exhibit 99.1).
- Confirm the voting percentages for the approved proposals to assess shareholder support levels.
- Review the Company's most recent Form 20-F or quarterly reports for actual financial performance data, as this filing contains none.